Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs KD 026 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Kadmon Corporation; Response Pharmaceuticals
- 15 Apr 2016 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 26 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 May 2015 New trial record